HUMIRA approved for non-infectious panuveitis treatment
On the 15th, Abbvie Korea(CEO Hong-Ki Yoo) and Eisai Korea(CEO Hong-Byung Ko) announced they acquired the Korean Ministry of Food and Drug Safety’s approval for the non-infectious intermediate, posterior and panuveitis treatment for adults who have had an inadequate response to corticosteroid.
H...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
